| Name | Title | Contact Details |
|---|
Health Communication Systems is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NextGate`s mission is to address the fundamental challenge of data management in the healthcare industry: the uncertainties and missed opportunities caused by duplicate and disconnected records in a data population. While implementing interface engine technology for hospitals in the early 1990s, we noticed a troubling trend – as application systems became integrated and exchanged data with each other, problems caused by duplicate and incomplete patient records (previously confined to one system and its MPI) multiplied and contaminated the data quality of other systems. Because this technical issue could impact a patient`s health, we made it our goal to find a solution. The result was MatchMetrix®, a technology platform that invokes probabilistic and other algorithms to identify duplicate and potentially duplicate records within a single data set or across multiple data sets. All records are assigned a unique ID that serves as an enterprise-wide universal key for accurate identification and efficient data exchange. Duplicate records are merged, related records are linked together, and all of them are indexed into a trusted, consistent, and reliable registry accessible to any authorized application or user. We continue to develop solutions that help manage information that facilitates care team collaboration with accuracy and reliability.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
Transonic Systems is a Ithaca, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blue Cross Blue Shield of Michigan is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Detroit, MI. To find more information about Blue Cross Blue Shield of Michigan, please visit www.bcbsm.com